{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:40:48Z","timestamp":1773456048587,"version":"3.50.1"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0240331","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T18:07:27Z","timestamp":1602180447000},"page":"e0240331","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Predicting the clinical outcome of melanoma using an immune-related gene pairs signature"],"prefix":"10.1371","volume":"15","author":[{"given":"Liangliang","family":"Meng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxi","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingtian","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8271-6605","authenticated-orcid":true,"given":"Yueyong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,10,8]]},"reference":[{"key":"pone.0240331.ref001","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3389\/fbioe.2020.00206","article-title":"Predicting the Risk of Melanoma Metastasis Using an Immune Risk Score in the Melanoma Cohort","volume":"8","author":"Y Sheng","year":"2020","journal-title":"Frontiers in bioengineering and biotechnology"},{"key":"pone.0240331.ref002","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-3-030-41008-7_3","article-title":"Immunotherapy for Melanoma","volume":"1244","author":"AA Albittar","year":"2020","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"pone.0240331.ref003","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"RL Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"pone.0240331.ref004","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ejso.2016.10.005","article-title":"Diagnosis and treatment of in-transit melanoma metastases","volume":"43","author":"A Testori","year":"2017","journal-title":"European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology"},{"issue":"10","key":"pone.0240331.ref005","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1586\/1744666X.2014.955851","article-title":"The immune escape in melanoma: role of the impaired dendritic cell function","volume":"10","author":"M Tucci","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"pone.0240331.ref006","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","volume":"14","author":"JJ Luke","year":"2017","journal-title":"Nature reviews Clinical oncology"},{"issue":"3","key":"pone.0240331.ref007","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S1470-2045(20)30062-0","article-title":"Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF(V600)-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial","volume":"21","author":"R Dummer","journal-title":"Lancet Oncol. 2020"},{"issue":"9992","key":"pone.0240331.ref008","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"GV Long","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"pone.0240331.ref009","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","article-title":"The Next Immune-Checkpoint Inhibitors: PD-1\/PD-L1 Blockade in Melanoma","volume":"37","author":"KM Mahoney","year":"2015","journal-title":"Clin Ther"},{"issue":"11","key":"pone.0240331.ref010","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/S1470-2045(16)30409-0","article-title":"Ipilimumab plus nivolumab for advanced melanoma","volume":"17","author":"JC Hassel","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"pone.0240331.ref011","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"JD Wolchok","year":"2013","journal-title":"New Engl J Med"},{"issue":"7","key":"pone.0240331.ref012","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1158\/2326-6066.CIR-18-0500","article-title":"A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients","volume":"7","author":"J Cursons","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"pone.0240331.ref013","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jdermsci.2016.12.006","article-title":"Melanoma long non-coding RNA signature predicts prognostic survival and directs clinical risk-specific treatments","volume":"85","author":"X Chen","year":"2017","journal-title":"J Dermatol Sci"},{"key":"pone.0240331.ref014","article-title":"A signature of 33 immune-related gene pairs predicts clinical outcome in hepatocellular carcinoma","author":"XY Sun","year":"2020","journal-title":"Cancer Med"},{"key":"pone.0240331.ref015","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.2147\/OTT.S200191","article-title":"An immune-related gene pairs signature predicts overall survival in serous ovarian carcinoma","volume":"12","author":"L Zhang","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"7","key":"pone.0240331.ref016","first-page":"1596715","article-title":"Development and validation of an immune-related gene pairs signature in colorectal cancer","volume":"8","author":"J Wu","year":"2019","journal-title":"#N\/A"},{"issue":"11","key":"pone.0240331.ref017","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jamaoncol.2017.1609","article-title":"Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer","volume":"3","author":"B Li","year":"2017","journal-title":"JAMA Oncol"},{"issue":"7","key":"pone.0240331.ref018","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"AM Newman","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"D1","key":"pone.0240331.ref019","doi-asserted-by":"crossref","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","article-title":"KEGG: new perspectives on genomes, pathways, diseases and drugs","volume":"45","author":"M Kanehisa","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"pone.0240331.ref020","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41596-018-0103-9","article-title":"Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap","volume":"14","author":"J Reimand","year":"2019","journal-title":"Nat Protoc"},{"issue":"5","key":"pone.0240331.ref021","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/pcmr.12495","article-title":"Acidic tumor microenvironment in human melanoma","volume":"29","author":"I Bohme","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"issue":"4","key":"pone.0240331.ref022","first-page":"1178","article-title":"A six-long non-coding RNA signature predicts prognosis in melanoma patients","volume":"52","author":"S Yang","year":"2018","journal-title":"Int J Oncol"},{"key":"pone.0240331.ref023","article-title":"A four-DNA methylation biomarker is a superior predictor of survival of patients with cutaneous melanoma","volume":"8","author":"W Guo","year":"2019","journal-title":"#N\/A"},{"issue":"1","key":"pone.0240331.ref024","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-018-0349-3","article-title":"Current landscape and future of dual anti-CTLA4 and PD-1\/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)","volume":"6","author":"YK Chae","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"Spec Issue","key":"pone.0240331.ref025","first-page":"41","article-title":"Combination Immunotherapy Superior to Monotherapy in Patients with Melanoma","volume":"8","author":"C Doyle","year":"2015","journal-title":"Am Health Drug Benefits"},{"issue":"5","key":"pone.0240331.ref026","first-page":"275","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"SL Topalian","year":"2016","journal-title":"#N\/A"},{"issue":"1","key":"pone.0240331.ref027","doi-asserted-by":"crossref","first-page":"e1002316","DOI":"10.1371\/journal.pcbi.1002316","article-title":"Senescent cells in growing tumors: population dynamics and cancer stem cells","volume":"8","author":"CA La Porta","year":"2012","journal-title":"PLoS Comp Biol"},{"issue":"3","key":"pone.0240331.ref028","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.taap.2006.11.021","article-title":"Melanoma differentiation associated gene-7\/interleukin-24 (mda-7\/IL-24): novel gene therapeutic for metastatic melanoma","volume":"224","author":"PB Fisher","year":"2007","journal-title":"Toxicol Appl Pharmacol"},{"issue":"11","key":"pone.0240331.ref029","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.ajpath.2019.08.002","article-title":"The Role of MET in Melanoma and Melanocytic Lesions","volume":"189","author":"Y Zhou","year":"2019","journal-title":"Am J Pathol"},{"issue":"1","key":"pone.0240331.ref030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10637-014-0167-5","article-title":"Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors","volume":"33","author":"I Puzanov","year":"2015","journal-title":"Invest New Drugs"},{"key":"pone.0240331.ref031","article-title":"Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response","author":"MJ Besser","year":"2020","journal-title":"Mol Carcinog"},{"key":"pone.0240331.ref032","article-title":"Adoptive cell transfer (ACT) of autologous tumor-infiltrating lymphocytes (TILs) to treat malignant melanoma: the dawn of a chimeric antigen receptor T (CAR-T) cell therapy from autologous donor","author":"L Roncati","year":"2020","journal-title":"Int J Dermatol"},{"issue":"3","key":"pone.0240331.ref033","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12032-018-1080-0","article-title":"as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma","volume":"35","author":"A Uryvaev","year":"2018","journal-title":"Med Oncol"},{"issue":"7","key":"pone.0240331.ref034","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"A Mantovani","year":"2017","journal-title":"Nature reviews Clinical oncology"},{"issue":"9","key":"pone.0240331.ref035","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"LB Ivashkiv","year":"2018","journal-title":"Nature reviews Immunology"},{"issue":"1","key":"pone.0240331.ref036","first-page":"1747340","article-title":"Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas","volume":"9","author":"AR Dancsok","year":"2020","journal-title":"#N\/A"},{"issue":"3","key":"pone.0240331.ref037","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41568-019-0106-z","article-title":"Immune control by amino acid catabolism during tumorigenesis and therapy","volume":"19","author":"H Lemos","year":"2019","journal-title":"Nature reviews Cancer"},{"issue":"8","key":"pone.0240331.ref038","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41568-018-0010-y","article-title":"Inflammatory breast cancer biology: the tumour microenvironment is key","volume":"18","author":"B Lim","year":"2018","journal-title":"Nature reviews Cancer"},{"issue":"4","key":"pone.0240331.ref039","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nri3642","article-title":"Democratizing systems immunology with modular transcriptional repertoire analyses","volume":"14","author":"D Chaussabel","year":"2014","journal-title":"Nature reviews Immunology"},{"issue":"11","key":"pone.0240331.ref040","first-page":"2482","article-title":"Oxidative Phosphorylation as an Emerging Target in Cancer Therapy. Clinical cancer research: an official journal of the","volume":"24","author":"TM Ashton","year":"2018","journal-title":"American Association for Cancer Research"},{"key":"pone.0240331.ref041","doi-asserted-by":"crossref","first-page":"108822","DOI":"10.1016\/j.cbi.2019.108822","article-title":"Clinical implications of ALDH1A1 and ALDH1A3 mRNA expression in melanoma subtypes","volume":"314","author":"JM Samson","year":"2019","journal-title":"Chem-Biol Interact"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0240331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T18:08:05Z","timestamp":1602180485000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0240331"}},"subtitle":[],"editor":[{"given":"Roger","family":"Chammas","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,10,8]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0240331","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,8]]}}}